← Back to all earnings calls
Guidance
from the 8-K filed Jul 28, 2026| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total net sales
table
Initiated
full year 2026
|
$5.13B – $5.26B | — | |
|
Opzelura net sales
table
Initiated
full year 2026
|
$1.05B – $1.1B | — | |
|
Hematology and Oncology net sales
table
Initiated
full year 2026
|
$860M – $890M | — | |
|
Total GAAP R&D and SG&A operating expenses
table
Initiated
full year 2026
|
$4.92B – $5B | GAAP | |
|
Total Non-GAAP R&D and SG&A operating expenses
table
Initiated
full year 2026
|
$4.63B – $4.7B | Non-GAAP |
Documents & deck
Item 2.02 release filed 2026-07-28
Open reading view
The quarterly report covering this quarter (filed 2026-07-28)
Open reading view